Please explain how you would set up and manage a quality assurance plan to watch over a clinical trial for a prospective interventional Phase 1 study that calls for eConsent and in-person study visits using a novel experimental vaccine in light of the COVID-19 pandemic. Potential difficulties with or without LAR, and how you intend to monitor accountabilities and report back to senior leadership, please describe your preparation and monitoring plan with regard to state and federal guidelines.